The Texas MPN Workshop: Second Annual Workshop and Meeting will take place from 19 - 20 August 2021 as a virtual event, bringing together leading experts to share the most recent and exciting new developments in the field of myeloproliferative neoplasms (MPNs), covering areas including novel JAK inhibitors, drivers of progression, clinical trial updates and more.
View all videos

Texas MPN Workshop 2021

The Second Annual Workshop and Meeting
19–20 August 2021 | Virtual Meeting

We spoke to @adamssperling (@DanaFarber), who shared some insights into the role of clonal hematopoiesis in multiple myeloma and other hematological malignancies:

🎥: http://ow.ly/GGiK50KVRjM

#MMsm #HemOnc #BloodCancerAwarenessMonth #IMS2022

We had a great interview with Catherine Coombs of @UNC, who shared some insights into novel BTK inhibitors in CLL and future outlooks.

@SocietyofHemOnc #SOHO22 #HemOnc #LeuSM #CLLsm

#SOHO22 | Peter Valk (@ErasmusMC) discusses TP53-mutated AML and MDS, the prognostic value of FLT3-ITD residual disease in AML, and more.

Visit http://VJHemOnc.com for our interviews from this year's meeting!

#SOHO2022 #HemOnc #LeuSM #AMLsm #MDSsm

At #SOHO22: Our Dr. Robert Orlowski discusses early data in bispecific T cell engagement for treatment of multiple myeloma. @Myeloma_Doc #EndCancer

Load More...

Texas MPN Workshop 2021

The Second Annual Workshop and Meeting
19–20 August 2021 | Virtual Meeting
The Texas MPN Workshop: Second Annual Workshop and Meeting will take place from 19 - 20 August 2021 as a virtual event, bringing together leading experts to share the most recent and exciting new developments in the field of myeloproliferative neoplasms (MPNs), covering areas including novel JAK inhibitors, drivers of progression, clinical trial updates and more.
View all videos

We spoke to @adamssperling (@DanaFarber), who shared some insights into the role of clonal hematopoiesis in multiple myeloma and other hematological malignancies:

🎥: http://ow.ly/GGiK50KVRjM

#MMsm #HemOnc #BloodCancerAwarenessMonth #IMS2022

We had a great interview with Catherine Coombs of @UNC, who shared some insights into novel BTK inhibitors in CLL and future outlooks.

@SocietyofHemOnc #SOHO22 #HemOnc #LeuSM #CLLsm

#SOHO22 | Peter Valk (@ErasmusMC) discusses TP53-mutated AML and MDS, the prognostic value of FLT3-ITD residual disease in AML, and more.

Visit http://VJHemOnc.com for our interviews from this year's meeting!

#SOHO2022 #HemOnc #LeuSM #AMLsm #MDSsm

At #SOHO22: Our Dr. Robert Orlowski discusses early data in bispecific T cell engagement for treatment of multiple myeloma. @Myeloma_Doc #EndCancer

Load More...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter